A Rebuttal: Issues with the Assay of Factor VIII Activity in Plasma and Factor VIII Concentrates

• References

• 1 Lundblad RL, Kingdon HS, Mann KG, White GC. Issues with the assay of factor VIII activity in plasma and factor VIII concentrates. Thromb Haemost 2000; 84: 942-8.
• 2 Rosén S, Andersson M, Blombäck M, Hägglund U, Larrieu MJ, Wolf M, Boyer C, Rothschild C, Nilsson IM, Sjörin E, Vinazzer H. Clinical application of a chromogenic substrate method for determination of factor VIII activity. Thromb Haemost 1985; 54: 818-23.
• 3 Barrowcliffe TW. Recommendations for the assay of high-purity factor VIII concentrates. Thromb Haemost 1993; 70: 876-7.
• 4 Brekkan E, Wrangel M, Sandberg H. The binding kinetics of B-domain-deleted recombinant factor VIII and plasma-derived factor VIII to phospholipid vesicles. Thromb Haemost Suppl 1999; 235.
• 5 Mikaelsson M, Oswaldsson U, Sandberg H. Influence of phospholipids on the assessments of factor VIII activity. Haemophilia 1998; 4: 646-50.
• 6 Oswaldsson U, Karlström K, Lidén Y, Sigte J, Ardalani K, Mikaelsson M. Comparison of different APTT-reagents in the one-stage assay of factor VIII concentrates. XXIV Congress of the World Federation of Hemophilia. 2000 Poster presentation.
• 7 Mikaelsson M, Oswaldsson U, Frank L. Comparison of activity and antigen measurements in a pharmacokinetic study of recombinant factor VIII SQ. XXIII Congress of the World Federation of Hemophilia. 1998 Poster presentation.
• 8 Sandberg H, Almstedt A, Brandt J, Gray E, Holmqvist L, Oswaldsson U, Sebring S, Mikaelsson M. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-FVIII SQ. Thromb Haemost 2001; 85: 93-100.
• 9 Barrowcliffe TW, Raut S, Hubbard AR. Discrepancies in potency assessment of recombinant factor VIII concentrates. Haemophilia 1998; 4: 634-40.